GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (FRA:8AP) » Definitions » E10

Agios Pharmaceuticals (FRA:8AP) E10 : €-1.38 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Agios Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was €-1.662. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.38 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Agios Pharmaceuticals was 8.20% per year. The lowest was 8.20% per year. And the median was 8.20% per year.

As of today (2025-03-02), Agios Pharmaceuticals's current stock price is €32.60. Agios Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was €-1.38. Agios Pharmaceuticals's Shiller PE Ratio of today is .


Agios Pharmaceuticals E10 Historical Data

The historical data trend for Agios Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals E10 Chart

Agios Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1.67 -2.00 -2.47 -1.38

Agios Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.58 -2.77 -1.24 -1.38

Competitive Comparison of Agios Pharmaceuticals's E10

For the Biotechnology subindustry, Agios Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Shiller PE Ratio falls into.



Agios Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.662/133.1571*133.1571
=-1.662

Current CPI (Dec. 2024) = 133.1571.

Agios Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -0.120 99.621 -0.160
201506 -0.757 100.684 -1.001
201509 -0.953 100.392 -1.264
201512 -0.991 99.792 -1.322
201603 -0.548 100.470 -0.726
201606 -1.308 101.688 -1.713
201609 -1.452 101.861 -1.898
201612 -1.270 101.863 -1.660
201703 -1.459 102.862 -1.889
201706 -1.584 103.349 -2.041
201709 -1.334 104.136 -1.706
201712 -1.529 104.011 -1.957
201803 -1.322 105.290 -1.672
201806 -1.019 106.317 -1.276
201809 -1.397 106.507 -1.747
201812 -1.389 105.998 -1.745
201903 -1.407 107.251 -1.747
201906 -1.655 108.070 -2.039
201909 -1.643 108.329 -2.020
201912 -1.440 108.420 -1.769
202003 -0.534 108.902 -0.653
202006 -1.163 108.767 -1.424
202009 -1.214 109.815 -1.472
202012 -1.159 109.897 -1.404
202103 22.638 111.754 26.974
202106 -1.170 114.631 -1.359
202109 -1.326 115.734 -1.526
202112 -1.540 117.630 -1.743
202203 -1.580 121.301 -1.734
202206 -1.589 125.017 -1.692
202209 -1.505 125.227 -1.600
202212 0.632 125.222 0.672
202303 -1.373 127.348 -1.436
202306 -1.394 128.729 -1.442
202309 -1.537 129.860 -1.576
202312 -1.577 129.419 -1.623
202403 -1.334 131.776 -1.348
202406 -1.570 132.554 -1.577
202409 14.614 133.029 14.628
202412 -1.662 133.157 -1.662

Add all the adjusted EPS together and divide 10 will get our e10.


Agios Pharmaceuticals  (FRA:8AP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Agios Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Agios Pharmaceuticals Headlines

No Headlines